Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,721.18
(
0.29%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 21799

Wednesday, 01/11/2006 8:12:28 AM

Wednesday, January 11, 2006 8:12:28 AM

Post# of 257266
>The cfo leaving shouldn't bother you because there weren't any revenues to screw around with.<

DNDN doesn’t have any material revenues either, and yet the announcement of the CFO’s departure there was a harbinger of poor performance for the stock.

As previously noted, among all of the top executives in a biotech company, the CFO has the least to gain and the most to lose by sticking around when there are problems not fully known to investors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today